Analysts Expect Spero Therapeutics Inc (NASDAQ:SPRO) Will Announce Earnings of -$0.57 Per Share
Analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to announce earnings per share of ($0.57) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Spero Therapeutics’ earnings. The highest EPS estimate is $0.19 and the lowest is ($0.87). Spero Therapeutics posted earnings per share of ($0.69) in the same quarter last year, which would suggest a positive year-over-year growth rate of 17.4%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that Spero Therapeutics will report full-year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.65) to ($2.12). For the next year, analysts forecast that the business will post earnings of ($3.53) per share, with EPS estimates ranging from ($4.11) to ($3.21). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.49. The company had revenue of $7.72 million during the quarter, compared to the consensus estimate of $1.25 million. Spero Therapeutics had a negative net margin of 342.70% and a negative return on equity of 34.34%.
Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Marshall Wace LLP purchased a new position in shares of Spero Therapeutics in the first quarter worth $39,000. Rhumbline Advisers purchased a new position in shares of Spero Therapeutics during the fourth quarter worth $62,000. PNC Financial Services Group Inc. raised its holdings in shares of Spero Therapeutics by 58.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock worth $98,000 after purchasing an additional 5,800 shares during the last quarter. IHT Wealth Management LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter worth $115,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Spero Therapeutics during the third quarter worth $126,000. 46.70% of the stock is owned by institutional investors and hedge funds.
NASDAQ SPRO opened at $10.38 on Friday. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $18.23. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.04.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Further Reading: What is the formula for the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.